HomeCompareMTST vs MRK

MTST vs MRK: Dividend Comparison 2026

MTST yields 333333.33% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTST wins by $8.099219044190773e+31M in total portfolio value
10 years
MTST
MTST
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full MTST calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — MTST vs MRK

📍 MTST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTSTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTST + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MTST pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTST
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MTST beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTST + MRK for your $10,000?

MTST: 50%MRK: 50%
100% MRK50/50100% MTST
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

MTST
No analyst data
Altman Z
-75.5
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTST buys
0
MRK buys
0
No recent congressional trades found for MTST or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTSTMRK
Forward yield333333.33%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$8.099219044190773e+31M$56.8K
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$8.098906375781879e+31M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MTST vs MRK ($10,000, DRIP)

YearMTST PortfolioMTST Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,206$366.19+$33.33MMTST
2$103,911,171,366$103,875,493,250.26$12,650$502.35+$103911.16MMTST
3$302,644,656,190,810$302,533,471,237,448.00$14,407$694.19+$302644656.18MMTST
4$823,817,797,451,856,400$823,493,967,669,732,100.00$16,585$967.82+$823817797451.84MMTST
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$19,342$1,363.89+$2095836995961804.00MMTST
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$22,913$1,947.19+$4983251920823461888.00MMTST
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$27,662$2,823.89+$1.1073835968753322e+22MMTST
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$34,159$4,173.35+$2.2999277308531335e+25MMTST
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$43,337$6,308.80+$4.464390519999121e+28MMTST
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$56,776$9,798.13+$8.099219044190773e+31MMTST

MTST vs MRK: Complete Analysis 2026

MTSTStock

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

Full MTST Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this MTST vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTST vs SCHDMTST vs JEPIMTST vs OMTST vs KOMTST vs MAINMTST vs JNJMTST vs ABBVMTST vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.